[Adobe Stock]
For example, one study revealed a remission rate of just 35% after as many as four antidepressant treatment trials (Pigott et al, 2022). However, recent advancements in neuroscience and technology are paving the way for a new era of personalized medicine known as precision psychiatry.
By identifying the specific neurobiological factors contributing to depression and incorporating objective, biological measures into treatment decision-making, clinicians can develop targeted interventions and personalize treatment selection to reduce time to therapy and improve outcomes.
The umportance of recognizing depression neurotypes
Dr. Kazu Okuda
Traditionally, depression has been treated as a singular condition, with patients receiving standard treatments such as antidepressants, psychotherapy, or a combination of both. However, this approach fails to recognize that depression is not a monolithic disorder but rather a spectrum of distinct subtypes, each with its own unique set of symptoms, underlying causes, and optimal treatment strategies.
According to The Diagnostic and Statistical Manual of Mental Disorders (or “DSM”), the definitive reference book on mental health and brain-related conditions and disorders published by The American Psychiatric Association (APA), there are 227 different combinations of symptoms that meet the criteria for diagnosing major depressive disorder.
Yet, even within 227 different ways to have depression, patients get treatment under the big umbrella of “depression.” Attempting to evaluate, diagnose, and treat depression with a one-size-fits-all approach based on subjective diagnostic criteria makes little sense.
The emergence of precision psychiatry aims to address this challenge by leveraging advances in neuroscience and technology to develop more targeted assessment tools for neurobiological features and treatment plans tailored to each patient’s unique needs. One promising avenue for achieving this goal is the use of neurotyping, which involves classifying patients based on their specific patterns of brain function. Employing a reliable, objective, neural measures and a data-driven approach can lead to more specific subgroups within the diagnosis, and therefore, better drug development and treatment of depression.
Neurotyping and the role of biomarkers
Neurotyping is a method used to biotype patients based on functional brain biomarkers, such as those obtained through electroencephalography (EEG), to identify distinct neural signatures associated with subtypes of depression. According to previous studies, the use of event-related potentials (ERPs) — the functional neural activity derived from the EEG in response to specific events — for neurotyping allows for a more nuanced understanding of individual patient profiles. This better understanding paves the way for tailored treatment plans that address the specific aspects of an individual’s depression. By utilizing these neural biomarkers, clinicians can develop personalized treatment plans that target the specific neurobiological systems involved in their particular subtype of depression.
The advent of portable and affordable EEG technology and innovative approaches like neurotyping are set to transform the landscape of depression treatment. Wireless clinical grade EEG headsets offer a patient-friendly and accessible diagnostic tool that can be used in various settings, making it easier to use data and objective measures to identify neurotypes of depression to inform the best treatment plan for each patient.
Neurotyping technology can also be applied in psychiatric and neurological clinical drug trials. By identifying subgroups of patients with distinct neural signatures who may be more likely to respond to specific therapies, neurotyping could inform patient selection criteria in clinical trials, potentially increasing the likelihood of detecting treatment effects and accelerating drug development.
Data-driven solutions for improved patient outcomes
As we move toward a future where precision psychiatry becomes the norm, it is essential to recognize the importance of a comprehensive approach to care that utilizes objective data and novel technologies. By embracing the concept of multiple “depressions” rather than a singular disorder, we can develop a more nuanced understanding of the complexities of this condition and provide patients with the individualized care they need to achieve optimal outcomes.
As the field of precision psychiatry continues to evolve, it is crucial for healthcare professionals, researchers, and policymakers to collaborate and invest in the development of innovative and objective assessment tools, personalized treatment options, and accessible care models. By doing so, we can transform the lives of the millions of individuals affected by depression and pave the way for a more effective approach to mental health care.
Dr. Kazu Okuda is co-founder and CEO of Universal Brain.
Filed Under: Psychiatric/psychotropic drugs
